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Simple Summary: Oral cancer is a devastating disease with increasing incidence worldwide. Oral
epithelial dysplasia (OED) is a potentially malignant disorder and patients with OED are at increased
risk of developing oral cancer. Current strategies for management of OED include surgery or
close observation and both fail to address the underlying pathogenesis of the disease. There is an
urgent need for evidence-based medical treatments for OED to prevent oral cancer development
in this cohort. Chemoprevention trials to date have not delivered therapeutic agents for routine
clinical practice. Historically, there has been significant heterogeneity in the design of oral cancer
chemoprevention trials, with most failing to selectively recruit patients with biopsy-proven OED,
which limits the usefulness of the findings in the OED population. The present paper aims to review
the current evidence and the methodology of early-phase trials in oral cancer chemoprevention.
Novel strategies in oral cancer chemoprevention will also be discussed.
Abstract: The increasing breadth of molecular targets, promise of immune-targeted therapies and
repurposed agents have heightened interest in cancer prevention. While, to date, testing of oral cancer
chemoprevention strategies has failed to deliver therapeutic agents for routine clinical practice, there
remains an urgent need for further clinical research to overcome this hurdle. Patients at the greatest
risk of disease stand to benefit the most from inclusion in clinical trials; therefore, there is a need to
carefully define this population using validated clinical and molecular markers. Safety, tolerability
and the efficacy of interventions is assessed through carefully selected endpoints. These endpoints
may include pharmacodynamic, clinical, histological and on-target molecular modifications as an
individual or as a composite endpoint. Early-phase trials provide an area of opportunity to explore
novel and repurposed agents in the setting of oral cancer chemoprevention, eventually leading to
phase III trials with clinical endpoints such as transformation and clinical outcome; these studies are
large, lengthy and expensive and should be reserved for the most promising of agents. This paper will
explore current evidence in oral cancer chemoprevention, drug repurposing, selection of appropriate
endpoints for early-phase trials and novel therapeutic angles in oral cancer chemoprevention.
Keywords: oral epithelial dysplasia; chemoprevention; early-phase trials; oral cancer prevention;
phase I; phase II; first-in-human
1. Introduction
Approximately 475,000 individuals are diagnosed with oral and oro-pharyngeal cancer
worldwide each year [1], with the main risk factors including smoking and smokeless
tobacco, betel nut, alcohol, human papillomavirus (HPV) infection and the presence of oral
potentially malignant disorders such as oral leukoplakia, lichen planus and oral submucous
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fibrosis [2,3]. Oral and oro-pharyngeal cancer are characterized by a poor prognosis, with
current data suggesting an overall mortality of approximately 47% (225,000 deaths per
year) [1].
The current model of oral and oro-pharyngeal cancer development suggests a progres-
sive multi-step transition from normal mucosa to oral squamous cell carcinoma (OSCC)
through a series of progressive histological changes (oral epithelial dysplasia) reflecting
the accumulation of genetic and epigenetic abnormalities and genetic susceptibility [4–7].
In patients with oral leukoplakia and other potentially malignant disorders, oral epithe-
lial dysplasia (OED) represents the main predictor of future cancer development [8,9].
Assessment and grading of OED is widely used in clinical practice to inform prognosis
and guide treatment: current data suggest that approximately 12% of individuals with
OED eventually progress to OSCC, with differential progression rates for mild/moderate
and severe dysplasia being 10% and 24%, respectively [8,10]. Management of OED is
controversial and there remains no widely accepted standard of care. The main aim of
OED treatment is to reduce the risk of/prevent cancer development; however, there is
a paucity of robust evidence to support any one strategy. Current management is lim-
ited to surgical excision or close surveillance [11], with both strategies failing to address
the molecular changes driving disease progression and the development of multiple and
multifocal dysplastic and malignant oral mucosal changes (field cancerization), which are
well-described characteristics of oral carcinogenesis [4,12,13]. A recent RCT of surgery
vs. observation in non-dysplastic leukoplakias failed to demonstrate an effect on cancer
outcomes between groups at median follow up of 72 months. In addition, there were
higher rates of worsening lesions/recurrence in the surgery group [14]. These findings
cannot be extrapolated to dysplastic oral lesions and further work is ongoing by the same
group to address this question [14].
Cancer chemoprevention represents an attractive alternative management strategy for
OED due to the potential to overcome the above limitations: it can (i) inhibit the process
of carcinogenesis and prevent the development of malignancy, (ii) avoid the morbidity
associated with surgery and (iii) tackle field cancerization. Furthermore, it may be useful in
preventing second primary tumours or recurrences in patients with a history of oral cancer.
Several oral cancer chemopreventative strategies have been explored through pre-
clinical studies and clinical trials but none have gained widespread acceptance [15], mostly
due to toxicity or lack of efficacy of the proposed agents and inconsistencies with respect
to study size, target population, inclusion criteria, outcomes measures and endpoints.
Designing a chemoprevention study is indeed challenging as, extrapolating from trials
in other precancer/cancer settings, trials should ideally incorporate clinical, histological
and molecular endpoints and observe participants for long enough to capture cancer
development, and possibly survival, as main clinical outcomes [16].
The present paper aims to review the current evidence and discuss the methodological
challenges behind the design of early-phase trials in oral cancer chemoprevention.
2. Management of Oral Epithelial Dysplasia: Current Standard of Care
Management of OED remains controversial and not evidence based. Although it is
widely accepted that the progression of OED to OSCC occurs only in a small subgroup
of patients, there is no robust method to identify these individuals. As a consequence, it
remains challenging for clinicians to select the individuals at high risk of progression who
would require surgical, potentially morbid, treatment vs. those who may be offered clinical
surveillance as they have indolent disease that is unlikely to progress. The current standard
of care consists of risk stratification based on histopathological OED grading and a number
of clinical factors that have been associated with the risk of OSCC development. Severe
OED is associated with a greater likelihood of progression to OSCC (24.1%) compared to
those with mild–moderate OED (10.3%) [8]. As a consequence, patients in this high-risk
group are often offered surgical excision of the area of OED in the attempt to reduce the
risk of future OSCC development. However, the outcomes of surgery in patients with
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OED vary widely among studies, and there remains little convincing evidence that surgical
excision of areas of OED is robustly associated with a reduction in the risk of oral cancer
development [17,18]. Furthermore, recurrence of OED [19–21] and OSCC development fol-
lowing surgery has been reported in up to 17% and 12% of cases, respectively [17,18,22–26].
Surgical excision may also be justified on the basis that, following an incisional biopsy
showing OED, occult OSCC foci can be detected in up to 10% of cases undergoing sub-
sequent surgical excision [27]. Nonetheless, surgery can be associated with significant
costs and morbidity, and may not be feasible in all cases due to various clinical and patient
factors. In addition, surgery does not address the issue of field cancerization and fails to
address the molecular changes driving disease progression.
Patients with mild and moderate OED are usually considered at lower risk of pro-
gression [28] and are often offered clinical surveillance (e.g., regular visual inspection) at
a variable frequency (from one to four times a year). The rationale is that the likelihood
of oral cancer development in these patients is substantially small and does not justify
the potential morbidity of surgical interventions. Exceptions include those patients with
mild/moderate OED who also present clinical factors associated with progression to OSCC,
and are therefore upgraded to high risk and managed accordingly (e.g., non-smoking status,
site, non-homogeneous appearance and size of the clinical lesion harbouring OED) [11,28].
Further biopsy is usually provided during surveillance if there is a clinical change in
the lesion suggesting possible progression to a higher grade of dysplasia [11]. There are
instances, however, where the additional biopsy reveals the presence of an already devel-
oped OSCC [29], which suggests that clinical surveillance may notably help with the early
detection of high-risk OED or early OSCC, but cannot reduce the risk of OED progressing
to malignancy per se.
3. Current Evidence in Oral Cancer Chemoprevention
Chemoprevention studies should ideally recruit participants at increased risk of pro-
gression to cancer to maximize (i) the event rate (oral cancer development) and
(ii) the potential benefit to the patient. Therefore, chemoprevention trials should selectively
recruit patients with a prognostic marker associated with a higher risk of oral cancer de-
velopment, such as OED and/or the presence of LOH at key loci [30,31]. Unfortunately,
the vast majority of previous chemoprevention trials have instead recruited individuals
at variable risk of progression; for example, patients with a diagnosis of oral leukoplakia
with/without OED. The chemopreventative agents used in previous studies (reviewed by
Lodi et al.) [15] include vitamin A or retinoids, β-carotene, NSAIDS, herbal extracts, topical
bleomycin and a Bowman–Birk inhibitor, for a total of 14 studies and 909 participants
(Table 1) [19,21,32–43]. These studies included patients with a diagnosis of oral leukoplakia
but did not mandate the presence of OED as an inclusion criterion. Only half of the studies
(7/14) reported information about the presence of OED at baseline, which ranged from
18 to 73%. Of note, the randomized, placebo-controlled trial by Mallery et al., which
investigated the potential chemopreventative effects of freeze-dried black raspberry gel
upon the risk of progression to cancer, recruited 40 patients all with a diagnosis of oral
intra-epithelial neoplasia (OED or atypia) [34]. Furthermore, the EPOC study recruited
patients with leukoplakia considered at high risk of progression due to the presence of
loss of heterozygosity (LOH) [44]. Mallery et al. reported a significant reduction in the
composite, surrogate endpoint of clinical, histological and LOH profile, after 3 months of
therapy between the active and placebo group [34]. The EPOC study found no significant
difference in cancer-free survival between intervention (erlotinib 150 mg OD 12 months)
and control groups with median follow up of 35 months [44] (see Section 7.1). The re-
maining studies reported by Lodi et al. reveal no clinical and/or histological response
to chemopreventive interventions in five studies [21,32,35,36,43], high recurrence rates
following an initial response in two [33,45] and some evidence of initial clinical response
in six of the studies [37,38,40–42]. Tsao et al. report some difference in clinical response
(reduction in lesion size) after 12 weeks of green tea therapy vs. placebo in hyperplastic
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and dysplastic oral lesions but no difference in cancer-free survival between groups at
27.5 months [37]. The remaining five studies [38–42] demonstrating a clinical and/or
histological response, detailed in Table 1, do not report follow-up data beyond 3 months of
cessation of the study treatment, thereby failing to show any evidence of any prolonged
treatment effect.
Drug Repurposing
The complexities, cost, failure rate and time associated with the development of new
anti-cancer agents have made drug repurposing an attractive option. Large epidemiological
studies have revealed the potential anti-cancer effects of existing drugs by chance, such
as aspirin [46,47], metformin [48] and sodium valproate [49]. There is often helpful data
detailing the safety profile and pharmacodynamics of established medications, meaning
that trials investigating the drug in a new setting can begin at phase II, rather than requiring
pre-clinical and phase I studies [50]. The so-called ‘in silico’ method, which uses high-
throughput screening to identify candidates for drug repurposing with desired action on
a pre-specified target, could help to pre-select drugs which may have a higher chance of
ultimate success in phase III trials [51].
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Table 1. Summary of randomised controlled trials from Lodi et al. (Information on number of patients with confirmed OED is reported where this information was available in the
published study.) PC—placebo controlled; DB—double blind; SB—single blind; BD—twice daily; TDS—three times daily; QDS—four times daily; OPML—oral premalignant lesion;
FU—follow up.
Author (Ref) Year Intervention Participants (n) Trial Design Inclusion Primary OutcomeMeasure Results
Armstrong [32] 2013 Bowman–Birk inhibitorconcentrate (BBIC) 3 g BD
132 recruited
89 completed






Change in lesion area at
6 months
No significant difference in
response rate (p > 0.94)
Hong [33] 1986
13-cis-retinoic acid (1 to 2
mg/kg/d) for
3 months + 6 months FU
44 randomised






Clinical: CR or PR in 16/24
retinoic acid vs. 2/20
placebo (p < 0.001);
histological response in
13/24 vs. 2/10 placebo
(p = 0.01). Recurrence within
2-3 months of cessation
Mallery [34] 2014
Freeze-dried black raspberries
(topically applied gel) 0.5g QDS
for 3 months
N = 40 2-arm, PC, DB, RCT
Microscopically confirmed
premalignant





9/22 BRB group high or
intermediate response vs.
0/18 placebo (p = 0.004).
Recurrence in 6/22 BRB and
7/17 placebo at 3 months
Mulshine [35] 2004
Ketorolac 0.1% mouthwash
10mL 30 seconds BD for 90 days
vs. placebo
N = 57 2-arm, RCT, PC; DB,randomised 2:1. Measurable oral leukoplakia Clinical response
Complete or partial
response: 11/37 ketorolac
vs. 6/19 placebo (p = 0.89)
Papadimitrakopolou [36] 2008
Oral celecoxib 100 mg (arm a) or
200 mg (arm b) or placebo (arm
c) BD for 12 weeks







arms were observed in any
of the response categories
(p > 0.05)
Tsao [37] 2009
Green tea 500, 750 or 1000
mg/m2 or placebo TDS
12 weeks
N = 39 Phase II, PC, DBdose-finding.






arms 50% vs. 18.2% placebo
(p = 0.09); histological
response 21.4% treatment
arms vs. 9.1% placebo
(p = 0.65). No difference in
cancer-free survival
between groups at median
27.5 months follow up
Sankaranaryan [45] 1997
Retinoids (vit A 300,000
IU/week) vs. β-carotene (360
mg/week) vs. placebo
N = 131 3-arm, DB, PC RCT Oral leukoplakia Cancer incidenceClinical response
Complete resolution: 22/42
vit A, 15/46 β-carotene,
3/46 placebo; p < 0.05.
Recurrence in 64% vit A and
53% β-carotene after 1 year
of cessation
Singh [38] 2004
β-carotene: Group A 4mg BD;
Group B 2md BD; Group C
placebo; all 3 months
N = 58 3-arm; PC; SB(pathologists)





in 11/20 Arm A; 5/20 Arm
B, 0/20 Placebo. (p < 0.001);
Group A and B showed
positive histological
response cf placebo
(p < 0.05). No follow up data
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Table 1. Cont.
Author (Ref) Year Intervention Participants (n) Trial Design Inclusion Primary OutcomeMeasure Results
Stich [39] 1988
Retinoids: Group A Placebo;
Group B: 200,000 IU/week
vitamin A. 6 months.






Remission in 1/33 placebo
and 12/21 vitamin A at
6 months
Histological changes only
assessed in vitamin A
group. No FU data on
recurrence
Piattelli [40] 1999 Isotretinoin 0.1% gel TDS vs.placebo; 4 months. N = 9 Cross-over, DB, PC.
Biopsy-proven oral
leukoplakia Clinical response
9/9 had ≥ 50%
improvement in size of
lesion with active
treatment at 4 months. No
further FU data
Li [41] 1999
Mixed Tea capsules (0.38 g
tea); 2 capsules QDS AND
mixed tea in glycerin (10%)











Partial regression in 11/29
(38%) of active treatment
arm vs. 3/30 (10%) in
placebo at 6 months;





vs. placebo 8-12 months
N = 112 2-arm, SB, PC, RCT Clinical diagnosis oforal leukoplakia Clinical response
Clinical improvement in
40/59 treatment gp vs.
9/53 placebo p < 0.01,





topically for 5 mins vs.
placebo for 2/52






Mean reduction in size:
bleomycin group 81% vs.
placebo 21% (p = 0.001); no
significant difference in
change in OED grade
between groups. Mean FU




β-carotene + 500 mg vitamin
C vs. active placebo (500 mg
vitamin C for 12 months)









placebo. p = 0.346. No
difference in
cancer endpoints
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4. Methodological Challenges in Clinical Trials of Oral Cancer Chemoprevention
4.1. Recruitment: Defining the High-Risk Population
The risk of oral cancer development in OED has been associated with a number of
clinical, histological and molecular variables. It has been suggested that patients with
the highest risk of developing the disease are selectively recruited to clinical trials to
maximize the event rate (development of oral cancer) and therefore minimize the number
of patients required to detect a difference in treatment effects [44]. This assumes that cancer
development is used as the primary outcome.
The mutational landscape of OSCC has been well characterized in recent years, with
the use of next-generation sequencing and high-throughput molecular profiling [52–54].
The pattern of molecular alterations changes from the premalignant state to the cancer
state; however, mutations are detected even early in the process of carcinogenesis [55].
Identification of a panel of mutations which accurately predict oral cancer development
may help to identify high-risk patients for targeted recruitment to clinical trials. LOH at
key sites (3p14, 9p21) has also been shown to be associated with a higher risk of oral cancer
development compared to LOH-negative lesions [30,56]. This has been translated into work
in non-smokers with OED which has demonstrated that the combination of non-smoking
status and LOH-positivity dramatically increases risk of oral cancer development [57].
Various clinical factors are known to be associated with a higher risk of oral cancer
development in OED including size of lesion > 200 mm2, heterogenous/speckled appear-
ance (erythroleukoplakia) and lateral tongue sub-site [23,28,58,59]. Clinical factors will
therefore remain an important aspect of risk stratification in OED until a biomarker or
panel of biomarkers has been validated and adopted into routine clinical practice. Grade of
dysplasia (WHO grade mild, moderate, severe) [60] can also be used to stratify patients
into higher and lower risk cohorts; moderate and severe oral epithelial dysplasia have
been shown to have a greater than two-fold increased risk of malignant transformation
compared to mild OED [12]. The issues of sampling error and intra- and inter-observer
variability continue to limit the predictive ability of histological grade as an isolated vari-
able [61]; however, its usefulness in clinical practice as a well-established diagnostic tool is
recognised.
No individual variable is able to reliably predict the future development of oral cancer
in an individual with OED. However, combinations of risk factors can be used to generate
a binary high- or low-risk profile which can then be used to guide management strategies
for that individual [11].
Selective recruitment of high-risk individuals is advantageous; these individuals
stand to gain the most from any intervention and, if cancer development is to be used as
an endpoint, it maximizes the event rate. Accurately defining the methodology around
selective recruitment and justification for this approach should be clearly reported to allow
comparability of trials.
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4.2. Choice of Endpoints
4.2.1. Pharmacodynamic and Pharmacokinetic
Pharmacodynamic (PD) endpoints are often used in phase 0 and phase I trials to
demonstrate proof of mechanism, i.e., the agent engages its intended molecular target
resulting in a (prior determined) desired alteration of the target function. This should
ultimately result in a cascade of events that leads to a clinical response. Pharmacokinetic
endpoints are also used to explore the absorption, distribution, metabolism and elimination
of a drug, if this has not been previously defined; establishing the relationship between
PK and PD endpoints is important in understanding dose–response [62]. This will usually
involve measuring plasma levels of drug at specified time intervals and correlating this
with patient drug diaries [63], as in Saba et al.’s study of erlotinib in OED [64].
4.2.2. Safety
Any medicinal product that is to gain regulatory approval must demonstrate a strong
safety record. Therefore, recording of adverse events is a requirement of all clinical trials of
investigational medicinal products. Adverse events (AEs) represent off-target occurrences
that may or may not be associated with the drug or product under investigation. Phase I
trials are often solely concerned with safety and may therefore not have a control group,
as the aim is not to show efficacy of the drug in question [65]. The aim of phase I trials
is often to determine maximum tolerated dose (MTD), which is the highest dose that
does not cause unacceptable side effects. The MTD has traditionally been determined via
rule-based designs, such as the 3 + 3 or A + B designs [66]. More recently, model-based
designs, such as the continual reassessment method (CRM), have gained acceptance as
more efficient methods in which a statistical model is used to estimate the relationship
between drug dose and disease-limiting toxicity (DLT) risk. Use of the CRM has been
shown to be more efficient in determining MTD and ensuring more patients are treated
close to MTD, compared to the 3 + 3 design [67]; however, expert statistical support is
required. Appropriate stopping rules must also be defined, usually based on number and
severity of adverse events, to ensure the safety of trial participants [68].
4.2.3. Surrogate Markers of Oral Cancer Development
Clinical
A measure of clinical response is universally reported in clinical trials in OED but
the method of defining clinical response varies [15]. Often a grading system is used to
categorize changes in size of the dysplastic lesion following intervention, with the changes
defined as complete, partial or no response [63,69]. To reduce intra- and inter-variability in
measurement of clinical lesions, Mallery et al. stipulated the use of an in-field ruler (Puritan
Stick ©) during clinical photography. This, together with the use of image software, allowed
blinded assessment of clinical photographs to determine changes in size of lesion [34],
which reduces bias in this measurement.
Histological
The use of ‘complete’ and ‘partial’ response categories has also been applied to
histological grading, using change in WHO grade of dysplasia pre- and post-treatment [64].
Cancers 2021, 13, 3845 9 of 18
Molecular
Molecular endpoints should be chosen based on good pre-clinical data that have
accurately defined the mechanism of action of the drug under investigation; the endpoint
should represent an on-target effect of the drug that is also associated with future risk of
cancer development [31,32,34,40–44,64,70].
4.2.4. Composite Endpoints
A composite endpoint consists of two or more distinct endpoints, known as compo-
nents [71]. Both the Mallery trial [34] and the SAVER trial [31] use the same composite
surrogate endpoint, which combines clinical, histological and molecular endpoints associ-
ated with cancer progression in OED. The benefit of combining endpoints in this way is
increased power to detect differences in the primary endpoint due to an increased num-
ber of ‘events’; this, in theory, allows smaller trials at lower cost and is attractive in the
case of OED where the event rate (oral cancer development) is low. Components of the
composite endpoint should all occur with similar frequency, have a clinically meaningful
interpretation and similar strength association with the disease in question. As described,
clinical factors (size of lesion), histological grade of dysplasia and LOH positivity have all
been strongly associated with oral cancer development, which makes this combination of
components as a composite endpoint plausible for trials in OED. These interpretations can
all be assessed blinded which adds to the credibility of trial design in reducing potential
bias from unblinded assessment in open-label trials.
4.2.5. Oral Cancer Development as an Endpoint
Lesions with histological evidence of OED are known to progress to oral cancer in
12% of cases, with a mean time to transformation of 4 years [8]. The annual malignant
transformation rate appears to be stratified by grade of dysplasia with a 3.57% rate for
severe OED compared to 1.7% for mild OED [72]. Cancer endpoints are considered the
gold standard in chemoprevention trials [15,73]; however, the low event rate that would be
expected in short-duration trials would necessitate large numbers to demonstrate efficacy,
which limits the usefulness of cancer endpoints in this context. Therefore, cancer endpoints
are best suited to large phase III trials in drugs with a proven track record in previous
early-phase trials.
4.3. Window of Opportunity Design
Window of opportunity trials use the time between diagnosis and treatment as an
opportunity to explore novel therapeutic strategies, without compromising standard of
care [74]. This is an attractive option, as diagnostic biopsies can often serve as the baseline
research biopsy and final surgical excision specimens can be sampled for the purposes of
collecting endpoint data. That is, it is possible to minimize and, in some cases, eliminate
the need for extra invasive samples for the purposes of research. This method is used in the
SAVER trial, where, in patients presenting with a new leukoplakia suspicious for dysplasia,
a screening biopsy for the trial also serves as the diagnostic biopsy. Patients scheduled for
surgery will have a punch biopsy at the time of surgery (at the 4-month point) and those
who are to be kept under observation undergo a second biopsy for the purposes of the
trial [31]. This window design is suitable for drugs with well-characterized pharmacoki-
netic profiles but where bioactivity in target tissue is yet to be established; for example, in
drug repurposing trials [74].
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5. The Need for a Core Outcome Set in OED Trials
The lack of chemoprevention trials in OED limits the ability to synthesize evidence in
meta-analysis and therefore limits the quality of the evidence base. The COMET initiative
was established in 2010 to promote the development of Core Outcome Sets (COS) in clinical
trials [75]. These COS are an agreed set of outcome measures that must be reported in
clinical trials within the specified disease. The outcomes included are usually determined
via a Delphi process and should include the patient perspective. The COS is a basic panel
of outcome measures, all of which must be reported; however, it is recognized that trials
should also record endpoints specific to the agent under investigation, such as on-target
molecular effects. There is no COS for clinical trials in OED and this should be addressed
to ensure the comparability of future studies in this area.
6. Initiatives in Oral Cancer Chemoprevention
There is recognition that achieving better outcomes in cancer prevention and treatment
involves significant investment and collaboration. The UK Experimental Cancer Medicines
Network (ECMC) was established in 2007 through joint investment by CRUK and NIHR
and health departments of the devolved nations, with the aim of assisting in the delivery
of early-phase cancer studies. Along with significant funding to support cancer prevention
research, the ECMC have published consensus guidelines on the effective delivery of com-
plex innovative design trials, which may be of relevance in the oral cancer chemoprevention
setting [76]. Oral cancer prevention strategies are high on the agenda for the World Health
Organisation (WHO) [77], with a global oral health action plan promised by 2023 and for
the International Association for Research on Cancer (IARC), who plan to publish an Oral
Cancer Prevention handbook, with a strong focus on tobacco cessation [78]. Similarly, the
National Cancer Institute supports research into oral cancer with around USD 20 million
of funding per annum and their Division of Cancer Prevention has a subdivision focused
on supporting phase 0/I/II trials, the ‘Consortia for Early Phase Prevention Trials’; the
NCI is currently supporting an early-phase trial of chemoprevention of oral cancer using a
mucoadhesive fenretinide patch in healthy volunteers [79].
7. Novel Strategies in Oral Cancer Chemoprevention
7.1. EGFR Inhibitors
The EPOC trial was a randomised, placebo-controlled, double-blind multi-centre trial
of erlotinib (an EGFR inhibitor) in the oral premalignancy setting, reported in 2016 [44].
Patients were eligible for randomisation if they had an oral premalignant lesion(s) with
or without history of oral cancer and evidence of LOH at key loci known to be associated
with progression to oral cancer [30]; the ‘LOH positive group’. Patients who did not have
evidence of LOH on screening (‘LOH negative group’) were not eligible for randomiza-
tion and did not receive any intervention but were followed up to assess incidence of
malignant transformation. Randomised patients (LOH-positive group) received either
erlotinib 150 mg once daily or matched placebo for 12 months. A total of 75 patients
were recruited to each group with a median follow up time of 35 months. There was no
difference in cancer-free survival in the treatment and control groups after 12 months of
treatment with erlotinib (HR 1.27; 95% CI, 0.68–2.38). However, when the LOH-positive
group was compared to the LOH-negative group, the former had significantly lower 3-year
cancer-free survival (HR 2.19; 1.25–3.83), which demonstrates the potential utility of LOH
as a predictive biomarker in OED. This trial was the first chemoprevention trial in OED to
selectively recruit patients based on risk of cancer using a biomarker (LOH), signifying a
move towards a more personalized approach to clinical trial recruitment.
7.2. MET-Targeted Therapy
Santigny et al. reported a microarray gene expression study of 86 leukoplakia samples
which identified 26 transcripts associated with increased risk of oral cancer develop-
ment [80]. Subsequently, the MET oncogene, a tyrosine kinase hepatocyte growth factor
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(HGF) receptor, was explored in a preclinical (murine model) study, which demonstrated
an association between high MET expression levels and oral cancer development [81].
Crizotinib (a multikinase inhibitor with activity against MET [82]) was shown to reduce
the frequency of progression from dysplasia to cancer in the mouse model. Therefore, MET
activation may be a potential early driver in oral premalignancy and therefore a possible
target for future chemoprevention studies.
7.3. Epigenetic Therapies
The term epigenetics is used to explain the connection between the genotype and the
phenotype of an organism. It is usually referred to as a genomic mechanism that reversibly
influences gene expression without altering DNA sequences. Examples of epigenetic modi-
fications include DNA methylation, histone modifications, chromatin remodelling and the
effects of non-coding RNA [83]. Epigenetic changes are highly variable within different
cells and tissues and changes are reversible. DNA hypermethylation at key promotor
sites (CDKN2A and CDKN2B) is strongly associated with HNSCC and has been observed
in precancerous oral tissues, meaning this could be an early event in oral carcinogene-
sis [84]. Histone acetylation is associated with a relaxed and open chromatin structure
which allows transcriptional activity [83]. Therefore, histone deacetylation is associated
with a transcriptionally repressive environment which can lead to tumorigenesis. Further,
histone modifications appear to occur at an early stage and accumulate during tumorige-
nesis [85]. Various histone deacetylases are overexpressed in HNSCC and this has led to
interest in HDAC inhibitors as therapeutic agents [86]. There are HDACs approved for
use in haematological malignancies and limited evidence in combination therapy for some
solid tumours [83]. The Kang study demonstrated a possible preventive effect of sodium
valproate (a short-chain fatty acid inhibitor of class I and II HDACs) in HNC [49]. It is
a well-established drug with a proven safety record in epilepsy and psychiatric disease.
Both time- and dose-dependent reductions in the incidence of HNC were demonstrated
(HR 0.57 95%CI 0.39–0.85); in addition, there is a plausible mechanism of action for cancer
prevention via HDAC inhibition, and therefore this is an attractive option for chemopreven-
tion trials in oral cancer. The SAVER trial is a multi-centre, randomised controlled trial of
SV in oral epithelial dysplasia in the UK and aims to recruit 110 participants to SV 500 mg
BD or observation arm [31]. This is a window of opportunity trial; patients randomised
to the treatment arm will take SV for 4 months, at which point the surrogate end points
will be captured and patients will revert to their pre-determined management pathway
(surgery or close surveillance). The feasibility of conducting such research will be explored
through monitoring recruitment rates and via an embedded qualitative study to explore
patients’ perceptions of the trial; both those who accepted and declined to participate. A
mechanistic sub-study will also explore the mechanism of action of SV in the OED setting.
7.4. Photoactivated Therapy
Photodynamic therapy (PDT) using systemic photosensitisers, such as FOSCAN, has
been explored with some good evidence of efficacy in early-stage oral cancers, and is
reviewed elsewhere [87]. However, patients were light-restricted for up to 6 weeks post
treatment and required a 7-day inpatient stay [88,89]. Some experienced significant pain
at the site of treatment and most required opioid analgesics for 1–2 weeks post treatment,
with 4–6 weeks healing time [88,89]. Therefore, conventional PDT does not appear to offer
significant advantages over surgery for early oral cancers in terms of morbidity or patient
experience. Topical PDT using 5-aminolevlunic acid and either laser or LED light source
has demonstrated good results in small studies [90,91] and a recent systematic review of
27 relevant studies concluded that PDT appears to offer advantages for oral potentially
malignant lesions refractory to other treatments. In addition, side effects of topical PDT are
mild and it remains an option for patients who refuse traditional surgical interventions [92].
LightOx, a commercial partnership invested in developing light-based therapies for oral
cancer, have developed a novel class of small-molecule, topically applied therapies, with
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phototoxic properties combined with hydroxamic acid to increase solubility [93]. The
compound is topically applied to the oral lesion and activation is performed using a dental
curing light, making this potentially suitable for application to OED lesions in an outpatient
setting. The topical nature makes systemic absorption unlikely; therefore, there will be no
lasting light sensitivity, as with conventional PDT. If the treatment is well tolerated and
effective, this would be a useful treatment modality for patients with lesions not amenable
to resection and could be used through repeat applications for patients with recurrent or
multiple lesions.
7.5. Immune Modulation in Oral Epithelial Dysplasia
7.5.1. Tumour Vaccines
Harnessing the immune system for cancer prevention is not a new concept; however,
there is growing interest in the development of non-viral cancer vaccines targeted against
tumour-specific and tumour-associated antigens [94,95]. The aim is to generate long-term
memory T-cell responses and make cancer cells more visible to the immune system, which
will then be activated at the earliest point in the process of carcinogenesis if or when
that occurs. Phase I and II trials are underway in the HNC setting and are described by
von Witzleben et al. [95]. Vaccinations appear to be most effective in this context prior
to disease initiation, in healthy individuals. This demonstrates the need to accurately
identify those at greatest risk of disease (oral cancer), prior to the development of OED.
The population of patients with OED would provide an ideal cohort for trials of cancer
vaccines in oral cancer prevention.
7.5.2. Immune Checkpoint Inhibitors
Immune checkpoint inhibitors, e.g., nivolumab, appear to represent a significant
breakthrough in the treatment of cancer, with evidence of improved overall survival in
oral cancer [96]. The aim of blocking PD-1-dependent immune checkpoints is to improve
the T-cell response against tumour cells and therefore reduce cancer-driven local immune
suppression. Whilst clinical evidence in OED is not yet reported, there is pre-clinical
evidence in a murine model which demonstrates that anti-PD-1 antibody reduced the
formation of OED lesions and prevented progression to OSCC [97]. A summary of current
immunotherapy clinical trials in OED is shown in Table 2, along with other ongoing or
recently completed oral cancer chemoprevention trials.
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Table 2. Summary of oral cancer chemoprevention trials, recruiting or recently completed.
Title Intervention Trial Design Primary Outcome Measure Location
Number of Participants; OED
Inclusion Criteria Other Info/Status
This Study is to Evaluate the
Safety and Pharmacokinetics of
SBS-101 in Patients With Oral
Premalignant Lesions
(NCT03939364)
Isotretinoin oral adhesive film





Overall response (complete or
partial response: clinical or
histological)
Treatment of emergent adverse
events
USA 24; any grade of histologicallyconfirmed dysplasia Not yet recruiting
A Randomized Study of
Sulindac in Oral Premalignant
Lesions (NCT00299195)







India 63; dysplasia, any grade Completed (awaiting results)
Metformin Hydrochloride in
Preventing Oral Cancer in




QDS for 2 weeks then BD for
10-12 weeks
Phase IIa; single-group,
open-label clinical trial Clinical response (lesion size) USA





Treating Patients with Oral
Leukoplakia (NCT00369174)
Rosiglitazone maleate 8 mg
OD 12 weeks
Phase II, single arm, open
label Clinical or histological response USA
25; any grade of dysplasia or
hyperplasia at a high-risk site Completed (awaiting results)
Pioglitazone Hydrochloride in
Preventing Head and Neck
Cancer in Patients with Oral
Leukoplakia (NCT00099021)
Pioglitazone
Hydrochloride once daily for
12 weeks
Phase II, single arm, open
label
Patient’s overall (clinical and
histological) response USA
21; includes hyperplasia at
high-risk oral sites or dysplasia
at any oral site
Completed (awaiting results).
Terminated early due to
good results
Safety and Efficacy of
Nivolumab in Treating Oral
Proliferative Verrucous
Leukoplakia (NCT03692325)
Nivolumab IV infusion day 1




Best overall response rate (time
frame: 2 years) USA
33; histologically confirmed PVL





every 3 weeks for 6 months
Phase II, single-arm,
open-label clinical trial
Clinical response at 6 months (%
patients with complete or
partial response)
USA 26; moderate or severe OED Recruiting
Immune Checkpoint Inhibitor
In High Risk Oral Premalignant
Lesions: IMPEDE
(NCT04504552)
Avelumab 800 mg IV; 4 cycles
over 8 weeks




transformation free survival up
to 30 months and change in
LOH status at 6 months
Italy 240; high risk oral premalignantlesions (with LOH) Recruiting




Sintilimab 8 cycles over
6 months
Phase II, open label, single
arm
Oral Cancer incidence rate at 2
years/clinical response of OPM
lesions
China 29; high-risk OED Not yet recruiting
Vandetanib in Preventing Head
and Neck Cancer in Patients
with Precancerous Head and
Neck Lesions (NCT01414426)








20; any grade of dyplasia plus
one “high risk” feature, e.g,
LOH at 3p or 9p
Completed (awaiting results)
Sodium valproate for epigenetic
reprogramming in the
management of high risk oral
epithelial dysplasia (SAVER)
Sodium valproate 500 mg BD




change in clinical, histological
and LOH score at 4 months
UK
110; any grade of dysplasia, if
mild must have 1+ high risk
feature
Recruiting
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8. Conclusions
There is an opportunity to explore the use of novel and repurposed drugs for oral
cancer prevention through careful design of early-phase clinical trials. There is a need
for development of core outcome sets in OED trials to reduce heterogeneity and ensure
comparability for data synthesis in future meta-analyses. Molecular-based approaches are
required to identify high-risk patients for recruitment to early-phase trials. These trials
should focus on drugs with a proven mechanism of action in phase 0 and phase I studies
and should aim to recruit patients with biomarkers of future disease that are associated
with the mechanism of action of the drug.
The oral cavity offers a unique opportunity for progress in early-phase chemopreven-
tion trials of both systemic and topical treatments; it is accessible for longitudinal clinical
monitoring of lesions and for cellular or tissue sample collection. Patients with OED
are at high risk of developing oral cancer compared to the general population; therefore,
recruitment of this cohort to well-designed, prospectively registered clinical trials with
strategies that aim to prevent the development of oral cancer should form an important
part of the overall oral cancer prevention strategy.
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